

NRTI Mutations:None

NNRTI Mutations:None

RT Other Mutations:A534S 100%  
seen:1562

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

INSTI Major Mutations:None

INSTI Accessory Mutations:None

IN Other Mutations:E11D 100%  
seen:1,110 • S24N 100%  
seen:1,625 • V31I 100%  
seen:1,618 • M50I 100%  
seen:1,280 • I60M 99%  
seen:2,887 • L63LI 1: 67% 1: 10%  
seen:2,789 • T112V 99%  
seen:6,890 • I113V 100%  
seen:6,890 • T124A 100%  
seen:6,862 • T125A 100%  
seen:6,862 • V126F 100%  
seen:6,862 • **I135NV** 1: 107% 1: 107%  
seen:7,623 • K136T 60%  
seen:7,626 • V163I 99%  
seen:9,886 • V201I 100%  
seen:6,297 • I203IM 1: 107% 1: 107%  
seen:1,305 • K211R 99%  
seen:1,303 • T218S 100%  
seen:1,792 • L234V 99%  
seen:1,006 • S283G 100%  
seen:2,302 • D186DG 1: 79% 1: 10%  
seen:2,180 • D288DG 1: 107% 1: 107%  
seen:2,262

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

IN comments

Other

- M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-naïve persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It may contribute to reduced DTG and CAB susceptibility in combination with R263K.

No drug resistance mutations were found for INSTI.